Write For Us

Covid-19 News: 70-80% Decline In Participants For Phase3 Trial Of Bharat Biotech's Covaxin

Sponsored Post Vitamin D2 Canada Persia
89 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

ava
Published
Covid-19 News: While the ICMR (Indian Council of Medical Research) has announced that results of Phase 1 trial of Covid vaccine candidate Covaxin, developed by Bharat Biotech, are "encouraging", the third phase of trials, which are currently going on in India, are facing challenges. According Dr Sanjay Rai, Principal Investigator of Phase 3 Covaxin trial at All India Institute of Medical Sciences (AIIMS), there is a 70% to 80% reduction in participation for the Covaxin trial. People are unwilling to participate in the trial because they think that a vaccine is coming for everyone soon. The AIIMS in Delhi needs 1,500 to 2,000 participants for Phase 3 trial of Covaxin, but only 200 have enrolled so far.

NDTV is one of the leaders in the production and broadcasting of un-biased and comprehensive news and entertainment programmes in India and abroad. NDTV delivers reliable information across all platforms: TV, Internet and Mobile.

Subscribe for more videos: https://www.youtube.com/user/ndtv?sub_confirmation=1
Like us on Facebook: https://www.facebook.com/ndtv
Follow us on Twitter: https://twitter.com/ndtv
Download the NDTV Apps: http://www.ndtv.com/page/apps
Watch more videos: http://www.ndtv.com/video?yt
Category
Asia
Tags
NDTV 24x7, Covid-19 News, ICMR
Sign in or sign up to post comments.
Be the first to comment